Analyst consensus rating
Structure Therapeutics Analyst Rating: Strong Buy
GPCR is rated Strong Buy by 15 analysts with a $104.77 target. As of 2026-09-01.
Direct answer
Structure Therapeutics's consensus rating is Strong Buy.
15 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $104.77.
Forecast evidence checked September 1, 2026.
Get free Structure Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $45.91
- Average price target
- $104.77
- High price target
- $145.00
- Low price target
- $69.50
- Low target gap
- +51.4%
- Target upside
- +128.2%
- High target gap
- +215.8%
- Target range width
- 164.5%
- Consensus rating
- Strong Buy
- Analysts
- 15
- Evidence date
- September 1, 2026
- Valid through
- September 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Structure Therapeutics?
Structure Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $104.77.
How far are Structure Therapeutics's low and high targets from the recorded price?
The low target implies +51.4%, while the high target implies +215.8%.
How many analysts are included in Structure Therapeutics's consensus?
The verified consensus includes 15 analysts.
How is Structure Therapeutics's target upside or downside calculated?
The average target of $104.77 is divided by the recorded price of $45.91, then one is subtracted to produce +128.2%. This does not guarantee a future return.
When was Structure Therapeutics's analyst forecast verified?
The data was verified on 2026-09-01. The dataset is valid through 2026-09-08.